Floatz logo

mk-2206

Metastatic Kidney Carcinoma

National Cancer Institute (NCI)Small moleculePhase 2Dormant
CCC
51/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
36/ 100
Competitive Position
81/ 100

Competitive context

42 Active assets in the Metastatic Kidney Carcinoma cohort.

Asset / SponsorPhaseRating
Nivolumab
Fondazione Policlinico Universitario Agostino Gemelli IRCCS
Phase 4BBB
Bms-907351
Fondazione Policlinico Universitario Agostino Gemelli IRCCS
Phase 4BB
Pembrolizumab
Fondazione Policlinico Universitario Agostino Gemelli IRCCS
Phase 4BB
Ipilimumab
Fondazione Policlinico Universitario Agostino Gemelli IRCCS
Phase 4BB
Epinephrine
Wake Forest University Health Sciences
Phase 3B

View all 50 →

Same molecule, other indications

mk-2206 is also rated in:

chronic lymphocytic leukemia/small lymphocytic lymphomaDormant
BB
Indicative ·
64 / 100
View asset →
diffuse large B-cell lymphomaDormant
B
Indicative ·
60 / 100
View asset →
prostate cancerDormant
B
Indicative ·
57 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →